• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

降解剂的抑制剂:药物研发中的范式转变。

Inhibitors to degraders: Changing paradigm in drug discovery.

作者信息

Haridas V, Dutta Souvik, Munjal Akshay, Singh Shailja

机构信息

Department of Chemistry, Indian Institute of Technology Delhi, Hauz Khas, New Delhi 110016, India.

Department of Chemistry, Indian Institute of Technology Palakkad, Palakkad, Kerala 678623, India.

出版信息

iScience. 2024 Mar 26;27(5):109574. doi: 10.1016/j.isci.2024.109574. eCollection 2024 May 17.

DOI:10.1016/j.isci.2024.109574
PMID:38646175
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11031827/
Abstract

The chemical understanding of biological processes provides not only a deeper insight but also a solution to abnormal biological functioning. Protein degradation, a natural biological process for debris removal in the cell, has been studied for years. The recent finding that natural degradation pathways can be utilized for therapeutic purposes is a paradigm shift in the drug discovery approach. Methods such as Proteolysis Targeting Chimera (PROTAC), lysosomal targeting chimera, hydrophobic tagging, AUtophagy TArgeting Chimera, AUTOphagy TArgeting Chimera and several other variants of these methods have made a considerable impact on the way of drug design. Few selected examples testify that a huge wave of change is on the way. The drug design based on the targeted protein degradation is a powerful tool in our arsenal. More molecules will be invented that will uncover the hidden secrets of biological functioning and provide enduring solutions to several unmet medical needs.

摘要

对生物过程的化学理解不仅能提供更深入的见解,还能为异常的生物功能提供解决方案。蛋白质降解作为细胞内清除碎片的自然生物过程,已被研究多年。最近发现自然降解途径可用于治疗目的,这是药物发现方法的一个范式转变。诸如蛋白酶靶向嵌合体(PROTAC)、溶酶体靶向嵌合体、疏水标记、自噬靶向嵌合体、自噬靶向嵌合体以及这些方法的其他几种变体等方法,已对药物设计方式产生了重大影响。少数精选的例子证明,一场巨大的变革浪潮即将到来。基于靶向蛋白质降解的药物设计是我们武器库中的一个强大工具。将会发明更多的分子,这些分子将揭开生物功能的隐藏秘密,并为一些未满足的医疗需求提供持久的解决方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ce/11031827/84f6c2e41e83/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ce/11031827/891c1cec6de4/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ce/11031827/1fe199852b96/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ce/11031827/179a16e51643/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ce/11031827/eac02d2639a4/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ce/11031827/f08cfc23ab4f/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ce/11031827/84f6c2e41e83/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ce/11031827/891c1cec6de4/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ce/11031827/1fe199852b96/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ce/11031827/179a16e51643/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ce/11031827/eac02d2639a4/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ce/11031827/f08cfc23ab4f/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ce/11031827/84f6c2e41e83/gr5.jpg

相似文献

1
Inhibitors to degraders: Changing paradigm in drug discovery.降解剂的抑制剂:药物研发中的范式转变。
iScience. 2024 Mar 26;27(5):109574. doi: 10.1016/j.isci.2024.109574. eCollection 2024 May 17.
2
Targeted protein degradation in drug development: Recent advances and future challenges.靶向蛋白降解在药物研发中的应用:最新进展与未来挑战。
Eur J Med Chem. 2023 Dec 5;261:115839. doi: 10.1016/j.ejmech.2023.115839. Epub 2023 Sep 27.
3
Effective degradation of EGFR mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems.通过基于 CRBN 的 PROTACs 有效降解 EGFR 突变蛋白,通过蛋白酶体和自噬/溶酶体降解系统。
Eur J Med Chem. 2021 Jun 5;218:113328. doi: 10.1016/j.ejmech.2021.113328. Epub 2021 Mar 7.
4
A Novel Lysosome Targeting Chimera for Targeted Protein Degradation via Split-and-Mix Strategy.一种新型溶酶体靶向嵌合体通过分裂-混合策略进行靶向蛋白降解。
ACS Chem Biol. 2024 May 17;19(5):1161-1168. doi: 10.1021/acschembio.4c00092. Epub 2024 Apr 25.
5
Targeted protein degradation via the autophagy-lysosome system: AUTOTAC (AUTOphagy-TArgeting Chimera).通过自噬溶酶体系统进行靶向蛋白降解:AUTOTAC(自噬靶向嵌合体)。
Autophagy. 2022 Sep;18(9):2259-2262. doi: 10.1080/15548627.2022.2091338. Epub 2022 Jun 26.
6
The state of the art of PROTAC technologies for drug discovery.PROTAC 技术在药物发现中的最新进展。
Eur J Med Chem. 2022 May 5;235:114290. doi: 10.1016/j.ejmech.2022.114290. Epub 2022 Mar 15.
7
Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.蛋白水解靶向嵌合体(PROTAC)在药物发现范式中的应用:最新进展与未来挑战。
Eur J Med Chem. 2021 Jan 15;210:112981. doi: 10.1016/j.ejmech.2020.112981. Epub 2020 Oct 31.
8
Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC).通过蛋白水解靶向嵌合体(PROTAC)发现有效的表皮生长因子受体(EGFR)降解剂。
Eur J Med Chem. 2020 Mar 1;189:112061. doi: 10.1016/j.ejmech.2020.112061. Epub 2020 Jan 14.
9
Advancing targeted protein degradation for metabolic diseases therapy.推进靶向蛋白降解治疗代谢疾病。
Pharmacol Res. 2023 Feb;188:106627. doi: 10.1016/j.phrs.2022.106627. Epub 2022 Dec 21.
10
Assays and technologies for developing proteolysis targeting chimera degraders.用于开发蛋白水解靶向嵌合体降解剂的分析方法和技术。
Future Med Chem. 2020 Jun;12(12):1155-1179. doi: 10.4155/fmc-2020-0073. Epub 2020 May 20.

引用本文的文献

1
LZTR1 is a melanoma oncogene that promotes invasion and suppresses apoptosis.LZTR1是一种促进侵袭并抑制凋亡的黑色素瘤癌基因。
Oncogene. 2025 Aug 30. doi: 10.1038/s41388-025-03538-2.
2
Emerging Concepts of Targeted Protein Degrader Technologies via Lysosomal Pathways.通过溶酶体途径的靶向蛋白质降解技术的新兴概念
Int J Mol Sci. 2025 Jun 11;26(12):5582. doi: 10.3390/ijms26125582.
3
Light-activatable photochemically targeting chimeras (PHOTACs) enable the optical control of targeted protein degradation of HDAC6.光激活光化学靶向嵌合体(PHOTACs)能够对HDAC6的靶向蛋白质降解进行光学控制。

本文引用的文献

1
Targeted protein degrader development for cancer: advances, challenges, and opportunities.靶向蛋白降解剂在癌症治疗中的开发:进展、挑战与机遇。
Trends Pharmacol Sci. 2023 May;44(5):303-317. doi: 10.1016/j.tips.2023.03.003.
2
Aptamer-LYTACs for Targeted Degradation of Extracellular and Membrane Proteins.用于靶向降解细胞外和膜蛋白的适体-溶酶体靶向嵌合体
Angew Chem Int Ed Engl. 2023 Apr 3;62(15):e202218106. doi: 10.1002/anie.202218106. Epub 2023 Feb 20.
3
Discovery of Norbornene as a Novel Hydrophobic Tag Applied in Protein Degradation.
RSC Med Chem. 2025 Mar 13. doi: 10.1039/d4md00972j.
4
Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions.靶向蛋白降解(TPD)在免疫治疗中的作用:了解蛋白水解靶向嵌合体(PROTAC)驱动的泛素-蛋白酶体相互作用。
Bioconjug Chem. 2024 Aug 21;35(8):1089-1115. doi: 10.1021/acs.bioconjchem.4c00253. Epub 2024 Jul 11.
发现降冰片烯作为一种新型疏水性标签应用于蛋白质降解。
Angew Chem Int Ed Engl. 2023 Mar 20;62(13):e202217246. doi: 10.1002/anie.202217246. Epub 2023 Feb 8.
4
Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer.选择性雄激素受体降解剂(SARD)克服去势抵抗性前列腺癌中的抗雄激素耐药性。
Elife. 2023 Jan 19;12:e70700. doi: 10.7554/eLife.70700.
5
Targeted Protein Degradation: Clinical Advances in the Field of Oncology.靶向蛋白降解:肿瘤学领域的临床进展。
Int J Mol Sci. 2022 Dec 6;23(23):15440. doi: 10.3390/ijms232315440.
6
Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin.一种新型PROTAC的开发,该PROTAC使用核酸适配体作为靶向配体,用于肿瘤选择性降解核仁素。
Mol Ther Nucleic Acids. 2022 Sep 19;30:66-79. doi: 10.1016/j.omtn.2022.09.008. eCollection 2022 Dec 13.
7
Discovery of E3 Ligase Ligands for Target Protein Degradation.E3 连接酶配体用于靶蛋白降解的发现。
Molecules. 2022 Oct 2;27(19):6515. doi: 10.3390/molecules27196515.
8
Emerging degrader technologies engaging lysosomal pathways.新兴的降解剂技术涉及溶酶体途径。
Chem Soc Rev. 2022 Oct 31;51(21):8832-8876. doi: 10.1039/d2cs00624c.
9
Recent Advances of Degradation Technologies Based on PROTAC Mechanism.基于 PROTAC 机制的降解技术的最新进展。
Biomolecules. 2022 Sep 7;12(9):1257. doi: 10.3390/biom12091257.
10
Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status.口服选择性雌激素受体降解剂(SERDs)在乳腺癌中的应用:进展、挑战和现状。
Drug Des Devel Ther. 2022 Sep 2;16:2933-2948. doi: 10.2147/DDDT.S380925. eCollection 2022.